scholarly journals RELATIONSHIP OF SERUM ADIPONECTIN AND RESISTIN LEVELS WITH THE SEVERITY OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B

Author(s):  
Nerma Čustović ◽  
Senija Rašić

Background: Recent research has closely linked adipocytokines to progression of liver inflammation and fibrosis in patients with non-alcoholic liver disease. The aim of this study was to determine the relationship ofserum adiponectin and resistin levels with the severity of liver fibrosis in patients with chronic hepatitis B (CHB), depending on the duration of antiviral therapy. Methods: The cross-sectional studyincluded75 patients with CHB divided into two groups: T1 group(on antiviral therapy for up to 2 years) and T2 group (on antiviral therapy over 2 years). Control group consisted of 40 healthy persons. Serum concentrations of adiponectin and resistin were estimated with ELISA method, while degree of liver fibrosis was determined using FIB-4and APRIscore. Results:The higher values of serum resistin concentration were verified in patients with CHBcompared to healthy controls. The mean level of serum resistin concentration was significantly higher in group of patients with higher FIB-4 score (9.12±3.39 vs. 5.58±3.36 ng/mL, p = 0.001), as well as APRI score (17.45 ± 3.96ng/mL vs.4.82 ± 1.11 ng/mL, p = 0.001). Positive correlation was found between serum resistin levels and degree of liver fibrosis (p < 0.001). There was no significant difference between mean serum adiponectin levels according to the values of FIB-4 and APRI scores. Conclusions:Serum resistin concentration could be a potential noninvasive biomarker of the severity of liver fibrosis in patients with chronic hepatitis B on antiviral therapy.

Author(s):  
Rika Andriany ◽  
Ibrahim Abdul Samad ◽  
Mansyur Arif

A liver biopsy is the gold standard for diagnosing and staging liver fibrosis in chronic hepatitis B patient but with many disadvantages so it is difficult to use as a routine examination. Research on index based on serum marker is helpful in predicting liver fibrosis. We conducted a study of the alpha-fetoprotein (AFP) and partial activated thromboplastin time (APTT) index or AA index in relation to the degree of liver fibrosis in chronic hepatitis B patients. This study was a retrospective cross-sectional study in dr.Wahidin Sudirohusodo Hospital Makassar by taking the data from medical records of chronic hepatitis B patients from January 2015 to December 2016. Samples were chronic hepatitis B patients who were tested for AFP, APTT and Fibroscan. The result showed the total of 79 chronic hepatitis B patients, 23 with severe fibrosis, 9 with moderate fibrosis, 26 with mild fibrosis, and 21 with no fibrosis. Spearman correlation test showed a significant correlation between the AA index and the degree of fibrosis (p <0.001) and showed a positive correlation between both of them with a very strong correlation (r = 0.830). Oneway Anova test showed a significant difference between the AA index and the  degree of fibrosis (p<0.001). The results of this study indicate that the AA index can be used as a predictor of fibrosis in chronic hepatitis B patients. It is suggested to do another study with larger sample based on the degree of fibrosis.


QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Marcel William Keddeas ◽  
Hany Haroun Kaisar ◽  
Hagar Ahmed Ahmed Elessawy ◽  
Mariam Samir Abdel Hamid Elewa

Abstract Background and aim Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel serum diagnostic marker for liver fibrosis in various liver diseases. We aimed to evaluate its role in assessment of liver fibrosis in chronic hepatitis B infection (CHB) with reference to liver stiffness measurement (LSM) by transient elastography (Fibroscan). Design and Methods A case control study. 50 CHB patients with LSM by transient elastography technology and retrievable serum samples and 20 normal volunteers as a control group were recruited. Results 50 CHB patients (M: F = 30:20; mean age 43years ± 10.58) and 20 normal control volunteers (M: F = 12:8; mean age 37years ± 14.5) were recruited. The mean M2BPGi values for control group, F0-F1, F2, F3 and F4 progressively increased with more advanced stages of liver fibrosis: 0.282, 0.719, 1.322, 1.65 and 1.904 COI, respectively (p &lt; 0.001). M2BPGi levels correlated well with liver stiffness (r = 0.911) and moderately with FIB-4 (r = 0.682), and with APRI (r = 0.536) (all p &lt; 0.001). Using cut-off values of 0.455, 1.02, 1.16, 1.66 and 1.71COI for control, F0-F1, F2, F3 and F4 groups, respectively, the AUROCs were 0.996, 0.996, 0.691, 0.794 and 1.00 for control, F0-F1, F2, F3 and F4 groups, respectively. There was a statistically significant but with weak positive correlation between M2BPGi serum level and INR (r = 0.333, p = 0.018). And there was a statistically significant but with weak negative correlation between M2BPGi serum level and platelet count (r = -0.41, p = 0.003) and HBV DNA (r = -0.373, p = 0.008).There was a statistically significance between M2BPGi serum level and the history of varices (p = 0.023) Conclusions WFA+-M2BP is an accurate serum indicator for assessing different stages of liver fibrosis. WFA+-M2BP provides a simple and reliable alternative or complementary method to liver biopsy and FibroScan.


Author(s):  
Hairul Anwar ◽  
Mutmainnah Mutmainnah ◽  
Ibrahim Abdul Samad

Chronic hepatitis B is an infectious liver disease caused by hepatitis B virus that persist for more than 6 months. Fibrosis is a result of fibrogenesis which is the formation of connective tissue (scarring) caused by liver tissue damage. Liver damage will affect the production of thrombopoetin causing disturbances in the balance between destruction and production of platelet resulting in decreased platelet counts. This study was a retrospective cross-sectional study by taking the data from medical records of chronic hepatitis B patients who were tested for complete blood count and fibroScan at the Dr.Wahidin Sudirohusodo Hospital Makassar from January 2014 to July 2016. The result showed a total of 323 chronic B hepatitis patients, 99 with severe fibrosis, 84 with moderate fibrosis and 140 with mild fibrosis. The Spearman correlation test showed a significant correlation between the platelet count and the degree of fibrosis (p <0.001) and showed a positive correlation between both of them with a very strong correlation (r = 0.802). The Kruskal-Wallis test showed a significant difference between platelet count and the degree of fibrosis (p<0.001). The conclusion is that a decreased platelet count is a sign of an increase in the degree of fibrosis in chronic hepatitis B patients. It is suggested to perform another study with larger samples based on the degree of fibrosis. 


Author(s):  
Yostila Derosa ◽  
Nasrul Zubir ◽  
Raveinal Arnelis

Background: Hepatitis B is acute or chronic liver inflammation caused by hepatitis B viral and can progress to hepatic chirrosis or liver cancer. Chronic hepatitis B has a high risk for liver fibrosis. Chronic inflammation and liver fibrosis are interrelated processes. This study aimed to determine the differences in T-regulator cells, Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) between chronic hepatitis B patients with and without liver fibrosis.Method: This study used a cross-sectional method for patients diagnosed with chronic hepatitis B in the Inpatient and Outpatient Department of the Internal Medicine Department  DR. M. Djamil Padang and other hospitals in Padang city for 6 months. Samples were selected by consecutive sampling according to inclusion and exclusion criteria. Liver fibrosis is identified by fibroscan. Data were analyzed by SPSS 21.0.Results: thirty-two patients were diagnosed with chronic hepatitis B and 50% had liver fibrosis. The levels of T-regulator cells in chronic hepatitis B patients without liver fibrosis were 2.08% and liver fibrosis 2.25%, but this difference was not statistically significant (p 0.05). Mean ALT levels in the group without fibrosis were 19 IU/L (7IU/L-71IU/L) and liver fibrosis 61 IU / L (13IU/L-625IU/L). The mean AST level in the group without fibrosis were 15.5 IU/L (10IU/L-32IU/L) and liver fibrosis 35.5 IU/L (10IU/L-476IU/L). The difference between ALT and AST in the two groups was significant (p 0.05). Hepatitis B patients with liver fibrosis had higher ALT and AST levels than without fibrosis.Conclusion: There were differences levels of T-regulator cells in the two groups, but it was not statistically significant. ALT and AST levels were higher in the liver fibrosis group and statistically significant.


2018 ◽  
Vol 154 (6) ◽  
pp. S-1132
Author(s):  
Choochai Teerawattananon ◽  
Supot Nimanong ◽  
Siwaporn P. Chainuvati ◽  
Phunchai Charatcharoenwitthaya ◽  
Tawesak Tanwandee ◽  
...  

2018 ◽  
Vol 12 (4) ◽  
pp. 10-15 ◽  
Author(s):  
Seyyed Saeed Sarkeshikian ◽  
Mohammad Reza Ghadir ◽  
Mahdi Jahangiri ◽  
Mansureh Molaei ◽  
Faezeh Alemi ◽  
...  

Author(s):  
Shendy Sherly Soeliauwan ◽  
Darwati Muhadi ◽  
Mutmainnah Mutmainnah

Chronic Hepatitis B involves liver parenchymal destruction leading to fibrosis. Decreased serum thrombopoietin associated with liver cell failure is thought as the leading cause of thrombocytopenia. Mean Platelet Volume (MPV) and Platelet Distribution Width (PDW) describe platelet size and degree of variation in platelet size respectively. The researchers intended to investigate whether platelet count, MPV, and PDW were variables to determine the severity of liver fibrosis in chronic hepatitis B patients. An observational study was carried out at the Dr. Wahidin Sudirohusodo Hospital Makassar from January 2015 until December 2016. A total of 100 chronic hepatitis B patients with negative HBeAg who underwent Fibroscan and complete blood count test were included in this study. A total of 100 chronic hepatitis B patients comprising, 11 with severe liver fibrosis, 16 with moderate liver fibrosis, 46 with mild liver fibrosis, and 27 with normal liver. There were significant differences in platelet count and MPV among liver fibrosis groups with p-value <0.001 and 0.046 respectively. No significant difference was observed for PDW among liver fibrosis groups (p=0.131). This study showed that platelet count and MPV were significantly different among the normal group, mild liver fibrosis group, moderate liver fibrosis group and severe liver fibrosis group in chronic hepatitis B patients. The researchers recommend to carry out studies with larger samples in number and distributed more evenly.


2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Sylvia Drazilova ◽  
Martin Janicko ◽  
Pavol Kristian ◽  
Ivan Schreter ◽  
Branislav Kucinsky ◽  
...  

Aim. To evaluate the compliance and virological response to pegylated interferon alpha 2a treatment of chronic hepatitis B in Roma population compared to majority Caucasian population in Slovakia.Methods. Retrospective evaluation of a cohort of all Roma patients treated with pegylated interferon alpha 2a from 2007 to 2013 in 3 centers for treatment of chronic viral hepatitis B. The Study included 43 Roma patients with chronic viral hepatitis B and randomly selected control group. Treatment duration was 48 weeks. Viral response was evaluated after 24 weeks, at the end of treatment, and 24 weeks after the end of treatment.Results. Complete treatment course was finished by 79.1% of Roma patients compared to all patients from the control groupp=0.0009. There was a tendency toward lower viral response rate in Roma at all time points; however significant difference was only at end of treatment viral response (51.2% Roma versus 81.4% majority,p=0.003). We also did not find significant difference at the rate of HBsAg loss.Conclusion. Roma patients with chronic hepatitis B have significantly worse compliance to treatment with pegylated interferon and they have significantly lower rate of end of treatment viral response.


2017 ◽  
Vol 112 (6) ◽  
pp. 882-891 ◽  
Author(s):  
Young Eun Chon ◽  
Jun Yong Park ◽  
Sung-Min Myoung ◽  
Kyu Sik Jung ◽  
Beom Kyung Kim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document